Jun 17, 2016 • 7:00 am EDT Corbus Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 22, 2016
Jun 16, 2016 • 7:00 am EDT Corbus Pharmaceuticals Announces Last Patient Enrolled in Phase 2 Study of Resunab for Systemic Sclerosis
May 16, 2016 • 8:13 am EDT Corbus Pharmaceuticals Reports 2016 First Quarter Financial Results and Provides Business Update
Apr 12, 2016 • 7:30 am EDT Corbus Pharmaceuticals Receives FDA Approval for Open-Label Extension to Its Phase 2 Trial of Resunab for Systemic Sclerosis
Mar 31, 2016 • 7:30 am EDT Corbus Pharmaceuticals Announces Addition of Phase 2 Clinical Protocol for Resunab Treatment of Systemic Lupus Erythematosus to FDA IND
Mar 29, 2016 • 7:30 am EDT Corbus Pharmaceuticals Reports 2015 Financial Results and Provides 2016 Business Update
Mar 7, 2016 • 7:35 am EST Corbus Pharmaceuticals Expands Clinical Development of Resunab(TM) With Phase 2 Trial for the Treatment of Systemic Lupus Erythematosus
Feb 1, 2016 • 7:05 am EST Corbus Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on February 9, 2016